Related Experiment Videos
Breast differentiation and its implication in cancer prevention.
Jose Russo1, Daniel Mailo, Yun-Fu Hu
1Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. J_russon@fccc.edu
Summary
A short treatment with human chorionic gonadotropin mimics pregnancy's protective genomic signature, offering a novel approach to breast cancer prevention. This method may inhibit cancer initiation and progression, challenging traditional long-term chemoprevention strategies.
Area of Science:
- Oncology
- Genomics
- Reproductive Biology
Background:
- Sporadic breast cancer is a leading cause of death in American women.
- Early full-term pregnancy is known to protect against breast cancer.
- The biological mechanism behind pregnancy-related breast protection involves a specific genomic signature.
Purpose of the Study:
- To explore a novel paradigm for breast cancer prevention.
- To investigate the potential of human chorionic gonadotropin (hCG) as a chemopreventive agent.
- To determine if hCG can induce the pregnancy-associated genomic signature.
Main Methods:
- Experimental studies in a model system.
- Administration of human chorionic gonadotropin (hCG).
- Analysis of genomic signature expression in breast tissue.
Main Results:
- A short course of hCG treatment induced the same protective genomic signature observed after a first pregnancy.
- hCG inhibited both the initiation and progression of mammary carcinomas in the experimental model.
- hCG treatment halted the development of early breast lesions, including intraductal proliferations and carcinoma in situ.
Conclusions:
- Human chorionic gonadotropin (hCG) shows significant potential as a novel chemopreventive agent for breast cancer.
- Short-term hCG administration, sufficient to induce the genomic signature, may protect normal cells from malignant transformation.
- This approach challenges the conventional view that chemopreventive agents require prolonged administration.